Cambridge Drug Discovery Company Profile

23:09 EST 19th November 2017 | BioPortfolio

Cambridge Drug Discovery, CDD, focus on the discovery of small molecules that modify cellular signalling. We are developing new assay methodologies for ion channels, GPCRs and kinases targets, including the application of our proprietary retroviral technology to develop new screening systems. Our expanding library collection of quality, diverse compounds (currently 100,000) and automated HTS system enables us to offer an integrated gene to screen service. Underpinning our gene to screen efforts is CDD's proprietary database, TargetBASE™ that encompasses bioinformatics and cheminformatics to integrate target and screening data. TargetBASE™ is a unique standalone product that is readily accessible for customised target analysis and selection.

CDD currently have 42 staff, including over 25 post-doctoral industrially trained scientists. Our purpose-built laboratories cover 12,000 sq ft and are located along side our administration building, on the Cambridge Science Park, Cambridge, UK.

CDD's core business is to provide drug discovery services and access to its technology portfolio through strategic outsourcing initiatives with biotech and pharmaceutical companies. Our internal R&D programme is focused on validating new technologies and identifying hit compounds from the CDD compound collection, for subsequent partnering programs. We expect to be in a position to partner lead compounds at the end of this year.


Cambridge Science Park, Milton Rd
United Kingdom


Phone: 01223 723 222
Fax: 01223 723 223

News Articles [1680 Associated News Articles listed on BioPortfolio]

Academic Drug Discovery 2016 March 22-23 2016 Cambridge, UK

SELECTBIO is pleased to announce Academic Drug Discovery 2016, which will be held on 22 – 23 March 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series. Attracting a global ...

Stem Cells in Drug Discovery 2016 April 5-6 2016 , Cambridge, UK

In June 2015 we launched Stem Cells in Drug Discovery in Cambridge, United Kingdom to a great response! Featuring presentations from Lorenz Mayr, Joseph Wu and Chris Ward, over 90 people attended, fro...

Cypralis Limited Announces Grant Award from Alzheimer’s Drug Discovery Foundation

Cambridge, UK, 1st March 2017 / Sciad Newswire / Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has been awar...

Cambridge Epigenetics strengthens leadership team

Cambridge Epigenetix has appointed Hayden Jeffreys as Chief Operating Officer (COO) and Dr Joanne Mason as Vice President (VP) of Biomarker Discovery.

New international consortium formed to speed up drug discovery in kidney diseases

A new international consortium, including academic institutions such as the Universities of Bristol and Cambridge and drugmaker Evotec, has been established to enhance the discovery of drugs to treat ...

Cambridge Research Biochemicals® launches second catalogue: DISCOVERY® Antibodies to the Life Science Community

Cleveland, UK, 21st February 2017 / Sciad Newswire / Cambridge Research Biochemicals® (CRB), a longstanding British company specialising in the synthesis of custom peptides and the generation of be...

U.K. Drug Developer Opens First U.S. Base In Metro Boston

NewsRxCelerate is an outsourced drug discovery and development company, founded in Cambridge, U.K. in 2012. The new U.S. operation is led by Laura Hamilton, who joined the company from the local ind...

The Current issue of “The view from here” is concerned with nanoscience in drug discovery.

The topic of this month’s newsletter from Drug Discovery Today is “nanoscience in drug discovery”

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Caraderma [A Refreshing Discovery, Inc.]

CaraDerma acne treatment

Polocaine [Dentsply Pharmaceutical]

3% Polocaine DENTAL (Mepivacaine Hydrochloride Injection, USP) 2% Polocaine DENTAL with Levonordefrin 1:20,000 (Mepivacaine Hydrochloride and Levonordefrin Injection, USP)

Xylocaine [Dentsply Pharmaceutical]

2% Xylocaine DENTAL with epinephrine 1:50,000 (Lidocaine HCl 2% and Epinephrine 1:50,000 Injection) 2% Xylocaine DENTAL with epinephrine 1:100,000 (Lidocaine HCl 2% and Epinephrine 1:100,000 Injection...

Articadent [Dentsply Pharmaceutical]

4% Articadent™ DENTAL with epinephrine 1:100,000 (Articaine hydrochloride 4% (40mg/mL) with epinephrine 1:100,000 injection) 4% Articadent™ DENTAL with epinephrine 1:200,000 (Articaine hydrochlori...

Gastromark [Mallinckrodt Inc.]

February 2010 300 mL 175 μg Fe/mL Gastromark™ [ferumoxsil, oral suspension] Mallinckrodt Inc. Rx only

PubMed Articles [3438 Associated PubMed Articles listed on BioPortfolio]

Protac-induced Protein Degradation in Drug Discovery: Breaking the Rules - or Just Making New Ones?

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer the...

From machine learning to deep learning: progress in machine intelligence for rational drug discovery.

Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence...

Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors.

Phosphodiesterases are proving to be fruitful targets for drug discovery. At the same time fragment-based drug discovery has matured into a powerful and widely applied technique. In this communication...

Allosteric Tuning of Caspase-7: a Fragment-Based Drug Discovery Approach.

The caspase family of cysteine proteases are highly sought after drug targets due to their essential roles in apoptosis, proliferation and inflammation pathways. High throughput screening efforts to d...

Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.

A considerable number of approved drugs show non-equilibrium binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy. Therefore, a detailed understanding o...

Clinical Trials [2071 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

Endometriosis Biomarker Discovery Study

This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients unde...

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

The purpose of the study is to better understand the function of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms. In Phase I, our propose ...

Biologic Basis of Liver Cancer From Chronic Hepatitis B

The focus of the study is to identify viral factors and host immune responses that differentiate HBV-related HCC patients from HBV patients who have not progressed to HCC. To that end, the...

Companies [2605 Associated Companies listed on BioPortfolio]

Sentinel Oncology Limited

Sentinel Oncology was founded in 2005 with the vision of developing an innovative strategy for cancer treatment, ‘Targeted Synergy’ in which a single drug can be engineered to deliver tw...

Cambridge Drug Discovery

Cambridge Drug Discovery, CDD, focus on the discovery of small molecules that modify cellular signalling. We are developing new assay methodologies for ion channels, GPCRs and kinases targets, includ...


Domainex — reducing drug discovery timelines, maintaining quality. Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug...

Ligon Discovery

Ligon Discovery is a Harvard University spinout that leverages a patented platform technology to identify pre-clinical drug candidates. The company's high-throughput microarray "chip" transforms the s...

Astex Therapeutics

Astex was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both...

More Information about "Cambridge Drug Discovery" on BioPortfolio

We have published hundreds of Cambridge Drug Discovery news stories on BioPortfolio along with dozens of Cambridge Drug Discovery Clinical Trials and PubMed Articles about Cambridge Drug Discovery for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Drug Discovery Companies in our database. You can also find out about relevant Cambridge Drug Discovery Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Corporate Database Quicklinks

Searches Linking to this Company Record